These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21812019)

  • 21. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
    Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
    Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
    Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
    Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
    Chavez JC; Piris-Villaespesa M; Dalia S; Powers J; Turba E; Nodzon L; Komrokji R; Sokol L; Locke FL; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Res; 2016 Aug; 47():78-83. PubMed ID: 27285853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Sorigue M; Orna E; Sancho JM
    Leuk Lymphoma; 2018 Nov; 59(11):2602-2611. PubMed ID: 29561206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
    Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
    Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
    Chanan-Khan A; Miller KC; Lawrence D; Padmanabhan S; Miller A; Hernandez-Illatazurri F; Czuczman MS; Wallace PK; Zeldis JB; Lee K
    Cancer; 2011 May; 117(10):2127-35. PubMed ID: 21523725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.
    Khouri MR; Jabbour EJ; Gulbis AM; Turturro F; Ledesma C; Korbling M; Samuels BI; Ahmed S; Alousi AM; Ciurea SO; Marin D; Patel KK; Popat UR; Bueso-Ramos CE; Bassett RL; Khouri IF
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1405-1410. PubMed ID: 28495642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
    Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
    Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
    Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
    Egle A; Steurer M; Melchardt T; Weiss L; Gassner FJ; Zaborsky N; Geisberger R; Catakovic K; Hartmann TN; Pleyer L; Voskova D; Thaler J; Lang A; Girschikofsky M; Petzer A; Greil R
    Ann Hematol; 2018 Oct; 97(10):1825-1839. PubMed ID: 29862437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
    Maurer C; Pflug N; Bahlo J; Kluth S; Rhein C; Cramer P; Gross-Ophoff C; Langerbeins P; Fink AM; Eichhorst B; Kreuzer KA; Fischer N; Tausch E; Stilgenbauer S; Böttcher S; Döhner H; Kneba M; Dreyling M; Binder M; Hallek M; Wendtner CM; Bergmann M; Fischer K;
    Eur J Haematol; 2016 Sep; 97(3):253-60. PubMed ID: 26643449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
    Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
    Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
    Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
    Palma M; Hansson L; Mulder TA; Adamson L; Näsman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Österborg A; Mellstedt H
    Eur J Haematol; 2018 Jul; 101(1):68-77. PubMed ID: 29569742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
    Chanan-Khan AA; Chitta K; Ersing N; Paulus A; Masood A; Sher T; Swaika A; Wallace PK; Mashtare TL; Wilding G; Lee K; Czuczman MS; Borrello I; Bangia N
    Br J Haematol; 2011 Nov; 155(4):457-67. PubMed ID: 22010965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
    Streetly M; Hunt BJ; Parmar K; Jones R; Zeldis J; Schey S
    Eur J Haematol; 2005 Apr; 74(4):293-6. PubMed ID: 15777340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
    Chen CI
    Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
    Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L; Wang DS; Lehman A; Chen CS; Johnson AJ; Marcucci G; Lee RJ; Lee LJ; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2008 Dec; 112(13):5180-9. PubMed ID: 18772452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.